Non-Hodgkin’s Lymphomas, Version 4.2014

Restricted access

Non-Hodgkin’s lymphomas (NHL) are a heterogeneous group of lymphoproliferative disorders originating in B lymphocytes, T lymphocytes, or natural killer cells. Mantle cell lymphoma (MCL) accounts for approximately 6% of all newly diagnosed NHL cases. Radiation therapy with or without systemic therapy is a reasonable approach for the few patients who present with early-stage disease. Rituximab-based chemoimmunotherapy followed by high-dose therapy and autologous stem cell rescue (HDT/ASCR) is recommended for patients presenting with advanced-stage disease. Induction therapy followed by rituximab maintenance may provide extended disease control for those who are not candidates for HDT/ASCR. Ibrutinib, a Bruton tyrosine kinase inhibitor, was recently approved for the treatment of relapsed or refractory disease. This manuscript discusses the recommendations outlined in the NCCN Guidelines for NHL regarding the diagnosis and management of patients with MCL.

  • 1.

    A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin’s lymphoma: the Non-Hodgkin’s Lymphoma Classification Project. Blood 1997;89:39093918.

    • Search Google Scholar
    • Export Citation
  • 2.

    Fisher RI, Dahlberg S, Nathwani BN. A clinical analysis of two indolent lymphoma entities: mantle cell lymphoma and marginal zone lymphoma (including the mucosa-associated lymphoid tissue and monocytoid B-cell subcategories): a Southwest Oncology Group study. Blood 1995;85:10751082.

    • Search Google Scholar
    • Export Citation
  • 3.

    Yatabe Y, Suzuki R, Tobinai K. Significance of cyclin D1 overexpression for the diagnosis of mantle cell lymphoma: a clinicopathologic comparison of cyclin D1-positive MCL and cyclin D1-negative MCL-like B-cell lymphoma. Blood 2000;95:22532261.

    • Search Google Scholar
    • Export Citation
  • 4.

    Hartmann EM, Campo E, Wright G. Pathway discovery in mantle cell lymphoma by integrated analysis of high-resolution gene expression and copy number profiling. Blood 2010;116:953961.

    • Search Google Scholar
    • Export Citation
  • 5.

    Iqbal J, Shen Y, Liu Y. Genome-wide miRNA profiling of mantle cell lymphoma reveals a distinct subgroup with poor prognosis. Blood 2012;119:49394948.

    • Search Google Scholar
    • Export Citation
  • 6.

    Fu K, Weisenburger DD, Greiner TC. Cyclin D1-negative mantle cell lymphoma: a clinicopathologic study based on gene expression profiling. Blood 2005;106:43154321.

    • Search Google Scholar
    • Export Citation
  • 7.

    Wlodarska I, Dierickx D, Vanhentenrijk V. Translocations targeting CCND2, CCND3, and MYCN do occur in t(11;14)-negative mantle cell lymphomas. Blood 2008;111:56835690.

    • Search Google Scholar
    • Export Citation
  • 8.

    Salaverria I, Royo C, Carvajal-Cuenca A. CCND2 rearrangements are the most frequent genetic events in cyclin D1(-) mantle cell lymphoma. Blood 2013;121:13941402.

    • Search Google Scholar
    • Export Citation
  • 9.

    Chen YH, Gao J, Fan G, Peterson LC. Nuclear expression of sox11 is highly associated with mantle cell lymphoma but is independent of t(11;14)(q13;q32) in non-mantle cell B-cell neoplasms. Mod Pathol 2010;23:105112.

    • Search Google Scholar
    • Export Citation
  • 10.

    Mozos A, Royo C, Hartmann E. SOX11 expression is highly specific for mantle cell lymphoma and identifies the cyclin D1-negative subtype. Haematologica 2009;94:15551562.

    • Search Google Scholar
    • Export Citation
  • 11.

    Zeng W, Fu K, Quintanilla-Fend L. Cyclin D1-negative blastoid mantle cell lymphoma identified by SOX11 expression. Am J Surg Pathol 2012;36:214219.

    • Search Google Scholar
    • Export Citation
  • 12.

    Avet-Loiseau H, Garand R, Gaillard F. Detection of t(11;14) using interphase molecular cytogenetics in mantle cell lymphoma and atypical chronic lymphocytic leukemia. Genes Chromosomes Cancer 1998;23:175182.

    • Search Google Scholar
    • Export Citation
  • 13.

    Determann O, Hoster E, Ott G. Ki-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: results from randomized trials of the European MCL Network and the German Low Grade Lymphoma Study Group. Blood 2008;111:23852387.

    • Search Google Scholar
    • Export Citation
  • 14.

    Garcia M, Romaguera JE, Inamdar KV. Proliferation predicts failure-free survival in mantle cell lymphoma patients treated with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with rituximab plus high-dose methotrexate and cytarabine. Cancer 2009;115:10411048.

    • Search Google Scholar
    • Export Citation
  • 15.

    Hsi ED, Jung S, Lai R. Ki67 and PIM1 expression predict outcome in mantle cell lymphoma treated with high dose therapy, stem cell transplantation and rituximab: a Cancer and Leukemia Group B 59909 correlative science study. Leuk Lymphoma 2008;49:20812090.

    • Search Google Scholar
    • Export Citation
  • 16.

    Schaffel R, Hedvat CV, Teruya-Feldstein J. Prognostic impact of proliferative index determined by quantitative image analysis and the International Prognostic Index in patients with mantle cell lymphoma. Ann Oncol 2010;21:133139.

    • Search Google Scholar
    • Export Citation
  • 17.

    Tiemann M, Schrader C, Klapper W. Histopathology, cell proliferation indices and clinical outcome in 304 patients with mantle cell lymphoma (MCL): a clinicopathological study from the European MCL Network. Br J Haematol 2005;131:2938.

    • Search Google Scholar
    • Export Citation
  • 18.

    Koletsa T, Markou K, Ouzounidou S. In situ mantle cell lymphoma in the nasopharynx. Head Neck 2013;35:E3337.

  • 19.

    Richard P, Vassallo J, Valmary S. “In situ-like” mantle cell lymphoma: a report of two cases. J Clin Pathol 2006;59:995996.

  • 20.

    Carvajal-Cuenca A, Sua LF, Silva NM. In situ mantle cell lymphoma: clinical implications of an incidental finding with indolent clinical behavior. Haematologica 2012;97:270278.

    • Search Google Scholar
    • Export Citation
  • 21.

    Swerdlow SH, Campo E, Seto M, Muller-Hermelink HK. Mantle cell lymphoma. In: Swerdlow SH, Campo E, Harris NL., eds. WHO classification of tumours of haematopoietic and lymphoid tissues (ed 4th). Lyon: IARC; 2008:229232.

    • Search Google Scholar
    • Export Citation
  • 22.

    Edlefsen KL, Greisman HA, Yi HS. Early lymph node involvement by mantle cell lymphoma limited to the germinal center: report of a case with a novel “follicular in situ” growth pattern. Am J Clin Pathol 2011;136:276281.

    • Search Google Scholar
    • Export Citation
  • 23.

    Adam P, Schiefer AI, Prill S. Incidence of preclinical manifestations of mantle cell lymphoma and mantle cell lymphoma in situ in reactive lymphoid tissues. Mod Pathol 2012;25:16291636.

    • Search Google Scholar
    • Export Citation
  • 24.

    Carbone A, Santoro A. How I treat: diagnosing and managing “in situ” lymphoma. Blood 2011;117:39543960.

  • 25.

    Romaguera JE, Medeiros LJ, Hagemeister FB. Frequency of gastrointestinal involvement and its clinical significance in mantle cell lymphoma. Cancer 2003;97:586591.

    • Search Google Scholar
    • Export Citation
  • 26.

    Salar A, Juanpere N, Bellosillo B. Gastrointestinal involvement in mantle cell lymphoma: a prospective clinic, endoscopic, and pathologic study. Am J Surg Pathol 2006;30:12741280.

    • Search Google Scholar
    • Export Citation
  • 27.

    Teodorovic I, Pittaluga S, Kluin-Nelemans JC. Efficacy of four different regimens in 64 mantle-cell lymphoma cases: clinicopathologic comparison with 498 other non-Hodgkin’s lymphoma subtypes. European Organization for the Research and Treatment of Cancer Lymphoma Cooperative Group. J Clin Oncol 1995;13:28192826.

    • Search Google Scholar
    • Export Citation
  • 28.

    Leitch HA, Gascoyne RD, Chhanabhai M. Limited-stage mantle-cell lymphoma. Ann Oncol 2003;14:15551561.

  • 29.

    Martin P, Chadburn A, Christos P. Intensive treatment strategies may not provide superior outcomes in mantle cell lymphoma: overall survival exceeding 7 years with standard therapies. Ann Oncol 2008;19:13271330.

    • Search Google Scholar
    • Export Citation
  • 30.

    Lacasce AS, Vandergrift JL, Rodriguez MA. Comparative outcome of initial therapy for younger patients with mantle cell lymphoma: an analysis from the NCCN NHL Database. Blood 2012;119:20932099.

    • Search Google Scholar
    • Export Citation
  • 31.

    Romaguera JE, Fayad L, Rodriguez MA. High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol 2005;23:70137023.

    • Search Google Scholar
    • Export Citation
  • 32.

    Romaguera JE, Fayad LE, Feng L. Ten-year follow-up after intense chemoimmunotherapy with rituximab-hyperCVAD alternating with rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma. Br J Haematol 2010;150:200208.

    • Search Google Scholar
    • Export Citation
  • 33.

    Merli F, Luminari S, Ilariucci F. Rituximab plus hyperCVAD alternating with high dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma, a multicentre trial from Gruppo Italiano Studio Linfomi. Br J Haematol 2012;156:346353.

    • Search Google Scholar
    • Export Citation
  • 34.

    Bernstein SH, Epner E, Unger JM. A phase II multicenter trial of hyperCVAD MTX/Ara-C and rituximab in patients with previously untreated mantle cell lymphoma; SWOG 0213. Ann Oncol 2013;24:15871593.

    • Search Google Scholar
    • Export Citation
  • 35.

    Howard OM, Gribben JG, Neuberg DS. Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival. J Clin Oncol 2002;20:12881294.

    • Search Google Scholar
    • Export Citation
  • 36.

    Lenz G, Dreyling M, Hoster E. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol 2005;23:19841992.

    • Search Google Scholar
    • Export Citation
  • 37.

    Rummel MJ, Niederle N, Maschmeyer G. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet 2013;381:12031210.

    • Search Google Scholar
    • Export Citation
  • 38.

    Visco C, Finotto S, Zambello R. Combination of rituximab, bendamustine, and cytarabine for patients with mantle-cell non-Hodgkin lymphoma ineligible for intensive regimens or autologous transplantation. J Clin Oncol 2013;31:14421449.

    • Search Google Scholar
    • Export Citation
  • 39.

    Inwards DJ, Fishkin PA, Hillman DW. Long-term results of the treatment of patients with mantle cell lymphoma with cladribine (2-CDA) alone (95-80-53) or 2-CDA and rituximab (N0189) in the North Central Cancer Treatment Group. Cancer 2008;113:108116.

    • Search Google Scholar
    • Export Citation
  • 40.

    Rummel MJ, Chow KU, Jager E. Treatment of mantle-cell lymphomas with intermittent two-hour infusion of cladribine as first-line therapy or in first relapse. Ann Oncol 1999;10:115117.

    • Search Google Scholar
    • Export Citation
  • 41.

    Spurgeon SE, Pindyck T, Okada C. Cladribine plus rituximab is an effective therapy for newly diagnosed mantle cell lymphoma. Leuk Lymphoma 2011;52:14881494.

    • Search Google Scholar
    • Export Citation
  • 42.

    Khouri IF, Romaguera J, Kantarjian H. Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma. J Clin Oncol 1998;16:38033809.

    • Search Google Scholar
    • Export Citation
  • 43.

    Khouri IF, Saliba RM, Okoroji GJ. Long-term follow-up of autologous stem cell transplantation in patients with diffuse mantle cell lymphoma in first disease remission: the prognostic value of beta2-microglobulin and the tumor score. Cancer 2003;98:26302635.

    • Search Google Scholar
    • Export Citation
  • 44.

    Lefrere F, Delmer A, Suzan F. Sequential chemotherapy by CHOP and DHAP regimens followed by high-dose therapy with stem cell transplantation induces a high rate of complete response and improves event-free survival in mantle cell lymphoma: a prospective study. Leukemia 2002;16:587593.

    • Search Google Scholar
    • Export Citation
  • 45.

    Dreyling M, Lenz G, Hoster E. Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network. Blood 2005;105:26772684.

    • Search Google Scholar
    • Export Citation
  • 46.

    Ritchie DS, Seymour JF, Grigg AP. The hyper-CVAD-rituximab chemotherapy programme followed by high-dose busulfan, melphalan and autologous stem cell transplantation produces excellent event-free survival in patients with previously untreated mantle cell lymphoma. Ann Hematol 2007;86:101105.

    • Search Google Scholar
    • Export Citation
  • 47.

    Tam CS, Bassett R, Ledesma C. Mature results of the M. D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma. Blood 2009;113:41444152.

    • Search Google Scholar
    • Export Citation
  • 48.

    van ‘t Veer MB, de Jong D, MacKenzie M. High-dose Ara-C and beam with autograft rescue in R-CHOP responsive mantle cell lymphoma patients. Br J Haematol 2009;144:524530.

    • Search Google Scholar
    • Export Citation
  • 49.

    Till BG, Gooley TA, Crawford N. Effect of remission status and induction chemotherapy regimen on outcome of autologous stem cell transplantation for mantle cell lymphoma. Leuk Lymphoma 2008;49:10621073.

    • Search Google Scholar
    • Export Citation
  • 50.

    Vandenberghe E, Ruiz de Elvira C, Loberiza FR. Outcome of autologous transplantation for mantle cell lymphoma: a study by the European Blood and Bone Marrow Transplant and Autologous Blood and Marrow Transplant Registries. Br J Haematol 2003;120:793800.

    • Search Google Scholar
    • Export Citation
  • 51.

    Geisler CH, Kolstad A, Laurell A. Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. Blood 2008;112:26872693.

    • Search Google Scholar
    • Export Citation
  • 52.

    Damon LE, Johnson JL, Niedzwiecki D. Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909. J Clin Oncol 2009;27:61016108.

    • Search Google Scholar
    • Export Citation
  • 53.

    Pott C, Hoster E, Beldjord K. R-CHOP/R-DHAP compared to R-CHOP induction followed by high dose therapy with autologous stem cell transplantation induces higher rates of molecular remission in MCL: results of the MCL younger intergroup trial of the European MCL Network [abstract]. Blood 2010;116:Abstract 965.

    • Search Google Scholar
    • Export Citation
  • 54.

    Hermine O, Hoster E, Walewski J. Alternating courses of 3x CHOP and 3x DHAP plus rituximab followed by a high dose ARA-C containing myeloablative regimen and autologous stem cell transplantation (ASCT) increases overall survival when compared to 6 courses of CHOP plus rituximab followed by myeloablative radiochemotherapy and ASCT in mantle cell lymphoma: final analysis of the MCL Younger Trial of the European Mantle Cell Lymphoma Network (MCL Net) [abstract]. Blood 2012;120:Abstract 151.

    • Search Google Scholar
    • Export Citation
  • 55.

    Delarue R, Haioun C, Ribrag V. CHOP and DHAP plus rituximab followed by autologous stem cell transplantation in mantle cell lymphoma: a phase 2 study from the Groupe d’Etude des Lymphomes de l’Adulte. Blood 2013;121:4853.

    • Search Google Scholar
    • Export Citation
  • 56.

    Geisler CH, Kolstad A, Laurell A. Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem-cell support: still very long survival but late relapses do occur. Br J Haematol 2012;158:355362.

    • Search Google Scholar
    • Export Citation
  • 57.

    Kahl BS, Longo WL, Eickhoff JC. Maintenance rituximab following induction chemoimmunotherapy may prolong progression-free survival in mantle cell lymphoma: a pilot study from the Wisconsin Oncology Network. Ann Oncol 2006;17:14181423.

    • Search Google Scholar
    • Export Citation
  • 58.

    Chang JE, Peterson C, Choi S. VcR-CVAD induction chemotherapy followed by maintenance rituximab in mantle cell lymphoma: a Wisconsin Oncology Network study. Br J Haematol 2011;155:190197.

    • Search Google Scholar
    • Export Citation
  • 59.

    Kluin-Nelemans HC, Hoster E, Hermine O. Treatment of older patients with mantle-cell lymphoma. N Engl J Med 2012;367:520531.

  • 60.

    Chang JE, Li H, Smith MR. Phase II study of VcR-CVAD with maintenance rituximab for untreated mantle cell lymphoma: an Eastern Cooperative Oncology Group Study (E1405). Blood 2014;123:16651673.

    • Search Google Scholar
    • Export Citation
  • 61.

    Goy A, Kahl B. Mantle cell lymphoma: the promise of new treatment options. Crit Rev Oncol Hematol 2011;80:6986.

  • 62.

    Fisher RI, Bernstein SH, Kahl BS. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol 2006;24:48674874.

    • Search Google Scholar
    • Export Citation
  • 63.

    Belch A, Kouroukis CT, Crump M. A phase II study of bortezomib in mantle cell lymphoma: the National Cancer Institute of Canada Clinical Trials Group trial IND.150. Ann Oncol 2007;18:116121.

    • Search Google Scholar
    • Export Citation
  • 64.

    O’Connor OA, Moskowitz C, Portlock C. Patients with chemotherapy-refractory mantle cell lymphoma experience high response rates and identical progression-free survivals compared with patients with relapsed disease following treatment with single agent bortezomib: results of a multicentre phase 2 clinical trial. Br J Haematol 2009;145:3439.

    • Search Google Scholar
    • Export Citation
  • 65.

    Goy A, Bernstein SH, Kahl BS. Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study. Ann Oncol 2009;20:520525.

    • Search Google Scholar
    • Export Citation
  • 66.

    Baiocchi RA, Alinari L, Lustberg ME. Phase 2 trial of rituximab and bortezomib in patients with relapsed or refractory mantle cell and follicular lymphoma. Cancer 2011;117:24422451.

    • Search Google Scholar
    • Export Citation
  • 67.

    Lamm W, Kaufmann H, Raderer M. Bortezomib combined with rituximab and dexamethasone is an active regimen for patients with relapsed and chemotherapy-refractory mantle cell lymphoma. Haematologica 2011;96:10081014.

    • Search Google Scholar
    • Export Citation
  • 68.

    Romaguera JE, Fayad LE, McLaughlin P. Phase I trial of bortezomib in combination with rituximab-hyperCVAD alternating with rituximab, methotrexate and cytarabine for untreated aggressive mantle cell lymphoma. Br J Haematol 2010;151:4753.

    • Search Google Scholar
    • Export Citation
  • 69.

    Cohen BJ, Moskowitz C, Straus D. Cyclophosphamide/fludarabine (CF) is active in the treatment of mantle cell lymphoma. Leuk Lymphoma 2001;42:10151022.

    • Search Google Scholar
    • Export Citation
  • 70.

    Levine AM, Tulpule A, Smith L. Results of a pilot trial of fludarabine, mitoxantrone and Rituxan in mantle cell lymphoma [abstract]. Blood 2005;106:Abstract 945.

    • Search Google Scholar
    • Export Citation
  • 71.

    Forstpointner R, Dreyling M, Repp R. The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2004;104:30643071.

    • Search Google Scholar
    • Export Citation
  • 72.

    Forstpointner R, Unterhalt M, Dreyling M. Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood 2006;108:40034008.

    • Search Google Scholar
    • Export Citation
  • 73.

    Rummel MJ, Kaiser U, Balser C. Bendamustine plus rituximab versus fludarabine plus rituximab in patients with relapsed follicular, indolent and mantle cell lymphomas: final results of the randomized phase III study NHL 2-2003 on behalf of the StiL (Study Group Indolent Lymphomas, Germany) [abstract]. Blood 2010;116:Abstract 856.

    • Search Google Scholar
    • Export Citation
  • 74.

    Robinson KS, Williams ME, van der Jagt RH. Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin’s lymphoma. J Clin Oncol 2008;26:44734479.

    • Search Google Scholar
    • Export Citation
  • 75.

    Friedberg JW, Vose JM, Kelly JL. The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma. Blood 2011;117:28072812.

    • Search Google Scholar
    • Export Citation
  • 76.

    Wiernik PH, Lossos IS, Tuscano JM. Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin’s lymphoma. J Clin Oncol 2008;26:49524957.

    • Search Google Scholar
    • Export Citation
  • 77.

    Habermann TM, Lossos IS, Justice G. Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma. Br J Haematol 2009;145:344349.

    • Search Google Scholar
    • Export Citation
  • 78.

    Reeder CB, Witzig TE, Zinzani PL. Efficacy and safety of lenalidomide oral monotherapy in patients with relapsed or refractory mantle-cell lymphoma: results from an international study (NHL-003) [abstract]. J Clin Oncol 2009;27:Abstract 8569.

    • Search Google Scholar
    • Export Citation
  • 79.

    Zinzani PL, Vose JM, Czuczman MS. Phase II multicenter study of the safety and efficacy of single-agent lenalidomide in subjects with relapsed/refractory mantle cell lymphoma: long-term follow-up analysis of the NHL-003 study [abstract]. Blood 2012;120:Abstract 2738.

    • Search Google Scholar
    • Export Citation
  • 80.

    Eve HE, Carey S, Richardson SJ. Single-agent lenalidomide in relapsed/refractory mantle cell lymphoma: results from a UK phase II study suggest activity and possible gender differences. Br J Haematol 2012;159:154163.

    • Search Google Scholar
    • Export Citation
  • 81.

    Goy A, Sinha R, Williams ME. Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study. J Clin Oncol 2013;31:36883695.

    • Search Google Scholar
    • Export Citation
  • 82.

    Wang L, Fayad L, Hagemeister FB. A phase I/IIstudy of lenalidomide in combination with rituximab in relapsed/refractory mantle cell lymphoma [abstract]. Blood 2009;114:Abstract 2719.

    • Search Google Scholar
    • Export Citation
  • 83.

    Wang M, Fayad L, Wagner-Bartak N. Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial. Lancet Oncol 2012;13:716723.

    • Search Google Scholar
    • Export Citation
  • 84.

    Advani RH, Buggy JJ, Sharman JP. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol 2013;31:8894.

    • Search Google Scholar
    • Export Citation
  • 85.

    Wang ML, Rule S, Martin P. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med 2013;369:507516.

  • 86.

    Hosing C, Saliba RM, McLaughlin P. Long-term results favor allogeneic over autologous hematopoietic stem cell transplantation in patients with refractory or recurrent indolent non-Hodgkin’s lymphoma. Ann Oncol 2003;14:737744.

    • Search Google Scholar
    • Export Citation
  • 87.

    van Besien K, Loberiza FR, Bajorunaite R. Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma. Blood 2003;102:35213529.

    • Search Google Scholar
    • Export Citation
  • 88.

    Bertz H, Illerhaus G, Veelken H, Finke J. Allogeneic hematopoetic stem-cell transplantation for patients with relapsed or refractory lymphomas: comparison of high-dose conventional conditioning versus fludarabine-based reduced-intensity regimens. Ann Oncol 2002;13:135139.

    • Search Google Scholar
    • Export Citation
  • 89.

    Vigouroux S, Michallet M, Porcher R. Long-term outcomes after reduced-intensity conditioning allogeneic stem cell transplantation for low-grade lymphoma: a survey by the French Society of Bone Marrow Graft Transplantation and Cellular Therapy (SFGM-TC). Haematologica 2007;92:627634.

    • Search Google Scholar
    • Export Citation
  • 90.

    Khouri IF, Lee MS, Saliba RM. Nonablative allogeneic stem-cell transplantation for advanced/recurrent mantle-cell lymphoma. J Clin Oncol 2003;21:44074412.

    • Search Google Scholar
    • Export Citation
  • 91.

    Maris MB, Sandmaier BM, Storer BE. Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma. Blood 2004;104:35353542.

    • Search Google Scholar
    • Export Citation
  • 92.

    Martin P, Chadburn A, Christos P. Outcome of deferred initial therapy in mantle-cell lymphoma. J Clin Oncol 2009;27:12091213.

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 895 249 20
PDF Downloads 155 95 4
EPUB Downloads 0 0 0